Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Miglitol

Increase in transaminase levels: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Matsubara A, et al. Safety and efficacy of miglitol (SEIBULE), an alpha-Glucosidase inhibitor, in Japanese patients with type 2 diabetes with liver dysfunction - A post-marketing prospective study of SEIBULE. Yakuri to Chiryo 46: 727-738, No. 5, 2018 [Japanese; summarised from a translation] - Japan Matsubara A, et al. Safety and efficacy of miglitol (SEIBULE), an alpha-Glucosidase inhibitor, in Japanese patients with type 2 diabetes with liver dysfunction - A post-marketing prospective study of SEIBULE. Yakuri to Chiryo 46: 727-738, No. 5, 2018 [Japanese; summarised from a translation] - Japan
Metadaten
Titel
Miglitol
Increase in transaminase levels: case report
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-50077-5

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Mesalazine

Case report

Multiple drugs

Case report

Docetaxel